We have identified an interaction between stefin B and nucleosomes, specifically with histones H2A.Z, H2B and H3. In synchronized T98G cells stefin B co-immunoprecipitated with histone H3, predominantly in the G1 phase of the cell cycle. Stefin B deficient mouse embryonic fibroblasts (MEFs) entered S phase earlier than wild type MEFs. In contrast, increased expression of stefin B in the nucleus delayed cell cycle progression in T98G cells. The delay in cell cycle progression was associated with the inhibition of cathepsin L in the nucleus, as judged from the decreased cleavage of the CUX1 transcription factor. In vitro, inhibition of cathepsin L by stefin B was potentiated in the presence of histones, while histones alone did not affect the cathepsin L activity. Interaction of stefin B with the M75 truncated form of cathepsin L in the nucleus was confirmed by fluorescence resonance energy transfer (FRET) experiments in the living cells. Stefin B could thus play an important role in regulating the proteolytic activity of cathepsin L in the nucleus, protecting substrates such as transcription factors from its proteolytic processing.
Cysteine cathepsins are involved in protein degradation (1) and the development and function of the immune system (2) . Cathepsin L is an endopeptidase that is able to perform limited proteolysis in the endosomes and lysosomes of specific cell types. Besides its role in hair formation and skin metabolism, it is involved in T-cell selection and NKT cell development (3) . It participates in processing the major histocompatibility complex (MHC) II invariant chain in thymic cortex epithelial cells (4) , encephalin in chromaffin granules of neuroendocrine cells (5) , and in the degradation and recycling of growth factors and their receptors in epidermal keratinocytes (6) . Cathepsin L is also associated with an endosomal processing step during invasion of cells by Ebola virus (7) , SARS coronavirus (8) and murine hepatitis coronavirus (9) . As the result of gene duplication, the human genome encodes for two cathepsin L-like proteases, namely the human cathepsin L and cathepsin V (cathepsin L2), whereas in mouse only cathepsin L is present (10) . At the protein level, mouse cathepsin L displays a higher sequence homology to human cathepsin V than to human cathepsin L (11) . Cathepsin V shares 80% protein sequence identity with cathepsin L, but in contrast to the ubiquitously expressed cathepsin L, its expression is restricted to thymus and testis (11, 12) .
Recently, the otherwise endosomal proteinase cathepsin L has been reported to be active in the nucleus. It cleaves the CUX1 transcription factor and as a result accelerates progression into the S phase of cell cycle (13) . Cathepsin L deficiency was shown to cause a global rearrangement of chromatin structure and redistribution of specifically modified histones (14) . In addition, cathepsin L was found to cleave histone H3.2 in the nucleus during mouse embryonic stem cell differentiation (15) .
Cathepsin L is inhibited in vitro by a number of proteins: cystatins (16), thyropins (17) and some of the serpins (18, 19) . Type 1 cystatins, or stefins, are mainly intracellular while type 2 cystatins are predominantly secreted (20, 21) . Stefin B is localised in the cytosol and nucleus of proliferating cells (22) . Loss-of-function mutations in the stefin B gene are found in patients with Unverricht-Lundborg disease (EPM1), but its physiological implication in the pathogenesis of the disease has yet to be defined (23) (24) (25) (26) . EPM1 is an autosomal recessive inherited disease in which patients suffer from myoclonic jerks, tonic-clonic epileptic seizures and progressive decline in cognition (26) . Histopathological examination of the brain has shown neural degeneration in several areas of the central nervous system, with cerebellar damage and serious alterations of Purkinje cells (27) . The most common mutation in EPM1 patients is a dodecamer repeat expansion in the stefin B gene promoter region that leads to reduced mRNA and protein levels (23, 25) . In addition, four mutations in the coding region were reported in EPM1 (23, 28) .
Not only cystatins, but also some other proteinase inhibitors are found in the nucleus. A serine proteinase inhibitor (serpin), the Myeloid and Erythroid Nuclear Termination stage-specific protein, MENT, was the first described cysteine proteinase inhibitor that interacts with chromatin and influences heterochromatin distribution (29, 30) .
The aim of our study was to identify proteins interacting with stefin B in the cell nucleus. The fundamental repeating unit of eukaryotic chromatin is the nucleosome, which is composed of an octamer of the four core histones H3, H4, H2A, H2B, around which 147 base pairs of DNA are wrapped (31). We have shown that stefin B interacts with the histones H2A.Z, H2B and H3 and with cathepsin L in living cells. In contrast to MENT, we found that nuclear cystatin/stefin B interacted with cathepsin L and with histones in the nucleus, but it did not bind to DNA. Our results suggest that stefin B regulates the activity of cathepsin L in the nucleus and protects the CUX1 transcription factor and probably other substrates from proteolytic cleavage by cathepsin L.
EXPERIMENTAL PROCEDURES
Antibodies -Antibodies to stefin B were described previously (32) . Rabbit polyclonal antibody to histone H3 (ab 1791), rabbit polyclonal to tri methyl K4 (H3K4me3) (ab 8580), and anti GFP antibody (ab290) were from Abcam. Antibodies to CUX 1 (861 and 1300) have been described (13) .
Mice -Stefin B (cystatin B)-deficient mice were created as described previously (33) . Stefin B-deficient mice were provided by Dr. R.M.
Myers, Stanford University (USA) and bred in our local colony. All mice were genotyped by PCR as previously described (33, 34) .
Mouse embryonic fibroblasts (MEF) -preparation and cell cycle synchronisation -
MEFs were prepared from individual embryos at embryonic day 14.5. The head and internal organs were removed, and the torso minced and dispersed in 0.1% trypsin (45- , that contains nuclear localisation signal (NLS) and targets the expressed protein to the nucleus, at Xho I and BamHI restriction sites. DNA sequence was determined using an ABI PRISM 310 Genetic Analyzer (Perkin Elmer, USA). The multiple cloning site (MCS) of pcDNA3 vector was changed prior to the insertion of T-Sapphire and Venus. This was done in two steps. The first linker, A, was constructed from two oligonucleotides, A: 5 -AAT TCT GCA GGT ATT CTT CAC ACT GGA GGC CGA CCG GGC C-3 and B: 5 -CGG TCG GCC TCC AGT GTG AAG AAT ACC TGC AG-3 complementary to A. This was ligated through EcoRI and ApaI restriction sites into pcDNA3 vector. All restriction sites between EcoRI and ApaI in MCS site of pcDNA3 vector were removed with linker A, among them the restriction site for XhoI and XbaI. Vector pcDNA3 with inserted linker A is labelled pcDNA3L/A. The second linker, B, was constructed from two oligonucleotides C: 5'-AGC TTC GTC CGC TCG AGA GCG CTT CTA GAG GTC TGG GAG GTT CAG GTG GAG GTG GAG CTG CTG CCG-3 (XhoI and XbaI site underlined) and D: 5 -GAT CCG GCA GCT CCA CCT CCA CCT GAA CCT CCC AGA CCT CTA GAA GCG CTC TCG AGC GGA CGA-3 , complementary to C. It was ligated through Hind III and BamHI restriction sites of pcDNA3L/A vector. PcDNA3L/A vector with inserted linker B is labelled pcDNA3L/AB. The cDNAs from Venus YFP (35) and TSapphire GFP (36) were amplified by PCR. The resulting products, after BamHI/EcoRI digestion, were cloned into pcDNA3L/AB expression vector. PcDNA3L/AB vector with inserted Venus is labelled Ven-pcDNA3L/AB, and with inserted T-Sapphire as T-Sap-pcDNA3L/AB. The cDNA clone for stefin B was PCR amplified and the resulting product cloned into T-SapphirepcDNA3L/AB after XhoI/XbaI digestion. T-SappcDNA3L/AB construct with inserted stefin B is labelled as St B-GFP. M75 cathepsin L was PCR amplified from procathepsin L cDNA (37), using forward (5'-GCC CGC CTC GAG ATG GCC ATG AAC GCC TTT GG-3'; XhoI site underlined) and reverse (5'-GTC CGC TCT AGA CAC AGT GGC GTA GCT GGC-3'; XbaI site underlined) oligonucleotides. The resulting product, after XhoI/XbaI digestion, was cloned into Venus-pcDNA3L/AB. The VenuspcDNA3L/AB construct with inserted M75 cathepsin L is labelled M75 cath L-YFP.
Cell culture -T98G human glioblastoma cell line, ATCC CRL-1690, was from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured as described (38) . T98G cells were transfected with pEF/myc/nuc/stefin B (NB) or empty pEF/myc/nuc vector alone (NO), using Lipofectamin 2000 (Invitrogen, The Netherlands), according to the manufacturer's instructions. Positive clones over-expressing stefin B in the nucleus were obtained after selection with Geneticin (G418) (Invitrogen, The Netherlands) (500 g/ml), and confirmed with Western blots and stefin B specific ELISA (32) . CHO-K1 cells (ATCC CCL-61) were cultured in DMEM medium supplemented with 10% FCS, 5 units/0.5 ml of penicillin and 5 g/0.5mL streptomycin at 37 °C in 5% CO 2 . For FRET analysis cells were seeded at a density of 1 x10 5 on cover glass slips and transiently transfected with 1 µg of StB-GFP and 1 µg M75 catL-YFP, using Lipofectamine 2000 (Invitrogen, The Netherlands), according to the manufacturer s recommendations. The expression of the GFP fusion proteins was determined by Western blot. MCF-7 cells (ATCC HTB-22) were cultured in DMEM medium supplemented with 10% FCS, 5 units/0.5 ml of penicillin and 5 g/0.5mL streptomycin at 37 °C in 5% CO 2 . Cells were grown on 10 cm petri dishes, transiently transfected with pEF/myc/nuc/stefin B (NB) or empty pEF/myc/nuc vector alone (NO), using Lipofectamine 2000 (Invitrogen, The Netherlands), according to the manufacturer's instructions. Cells were lysed 24 hours post transfection and nuclear cell lysates prepared as described (13) .
Preparation of cell lysates -Cell lysates were prepared as described (34) . Nuclear extracts were prepared by the method of Dignam et al. (39) , with minor modifications, including the use of a protease inhibitor cocktail (Cat.No.P8340; Sigma-Aldrich, Saint Louis, MO) and the addition of phenylmethylsulfonyl fluoride (PMSF; Fluka, Basel, Switzerland) (0.5 mM) to the resuspension and lysis buffers. Nuclear cell lysates from MCF-7 cells were prepared as described by Goulet et al (13) . In both cases, the supernatants were transferred to fresh test tubes and, if not used immediately, stored at -80 °C. Total protein concentration was determined using the Bradford assay (Bio-Rad, USA).
Co-immunoprecipitation -was performed as described (34) . 5 g anti-stefin B polyclonal or monoclonal antibodies (32) were added to nuclear lysates and allowed to rock at 4°C for 2 h or overnight. 50 l of protein A-Sepharose beads were then added to the lysates, which were allowed to rock for another hour at 4°C. Immunoprecipitates were washed three times in cold PBS. Samples were resolved on SDS-PAGE and analysed by Western blots.
Western blots -were performed as described (13, 34) . Equal amounts of protein were loaded and resolved in 15%, 12.5% or 6% SDS-PAGE gels and electrotransferred to nitrocellulose membranes. Proteins were visualized with ECL (Amersham, USA) according to the manufacturer' s instructions.
N-terminal sequencing -Edman sequence analyses of protein samples were performed on an Applied Biosystems Model 492A Procise Protein Sequencing System (Foster City, CA, USA). Proteins were electro-transferred from SDS-PAGE gels to PVDF membranes and sequenced using a pulsed-liquid blot sequencing protocol. PTH amino acid derivatives were analyzed online on a microbore HPLC system 140C (Applied Biosystems, USA) using an RP C18 Spheri-5 column (Brownlee, USA). Any cysteine residues were alkylated before sequencing. All reagents and solvents were of sequencing grade (Applied Biosystems, USA).
Cell cycle analysis -Cells were trypsinized and pellets fixed in 70% ethanol overnight at -20 °C. After washing, the cells were incubated for 30 min at 37 °C in PBS containing 40 g/ml propidium iodide (PI), 100 g/ml RNase and 0.05% (w/v) Triton X-100. Finally, cells were washed and resuspended in 0.5 ml PBS. Samples were analysed with a FACSCalibur flow cytometer (Becton Dickinson, USA) and cell cycle profiles were evaluated using CellQuest software (Becton Dickinson, USA), version 3.3. Fluorescence resonance energy transfer (FRET) microscopy -FRET measurements were made using a Leica TCS SP5 microscope equipped with a 405 nm laser. The images were acquired with 405 and 515 nm laser lines. Images were taken through a 63×1.4-numerical aperture oil immersion objective. To explore the interaction of the M75 truncated form of cathepsin L with stefin B, we used a fluorescent protein-protein pair that has excitation and emission properties favorable for FRET: the emission wavelength of T-Sapphire-GFP partially overlaps with the excitation wavelength of YFP (40) . For FRET experiments, transient transfections were performed as described above and expression levels of stefin B-GFP (donor) and M75 cathepsin L-YFP (acceptor) proteins were adjusted to similar levels by Western blot. FRET between stefin B-GFP and M75 cath L-YFP was measured in live cells plated on glass-bottomed culture dishes, 18-24h after transfection. Fluorescence was recorded at three different settings: GFP ex , 405 nm/GFP em 515 nm; YFP ex , 515 nm/YFP em , 523-535 nm; FRET ex , 405 nm/FRET em , 528-535 nm. Laser power and detector gain were adjusted in the different channels. The image of FRET was generated with the "PixFRET" plug-in for the ImageJ software at www.unil.ch/cig/page16989.html. In all FRET experiments, negative FRET controls were analysed after transfection or cotransfection of GFP/YFP or co-transfection R68X-GFP/M75 cath L-YFP (negative controls). Bleed-through coefficients were calculated using fret/donor or fret/acceptor image stacks captured from cells expressing only the donor or acceptor (41) Coefficients were averaged from at least 80 cells -40 separate stacks for each experiment.
Cathepsin L inhibition in vitro -Cathepsin L was pre-activated by incubation in 0.1 mM acetate, 1 mM EDTA, 0.1% (w/v) Brij-35, 0.02% (w/v) sodium azide, 10 mM cysteine, pH 5.5 for at least 10 min at room temperature before use. The active enzyme concentration was determined with trans-epoxysuccinyl-l-leucylamido-(4-guanidino)-butane (E-64) (Peptide Research Institute, Osaka, Japan) titration. Cathepsin L (final concentration 21.5 nM) was incubated for 5 minutes with histone isolated from calf thymus (H 4524, Sigma Aldrich, St. Louis, MO, USA) at final concentrations from 10.8 nM to 2.15 µM. When determining the stefin B and histone interactions, stefin B (final concentration 15 nM) was preincubated with final concentrations of histones from 10.8 nM to 2.15µM for 5 minutes, followed by the addition of cathepsin L (final concentration 21.5 nM). After the initial incubation steps, substrate Z-Phe-Arg-pNA (Bachem, AG, Switzerland) was added to 100 µM final concentration and initial velocity was determined spectrophotometrically at 410 nM.
RESULTS

Stefin B interacts with histones H2A.Z, H2B
and H3 in the nucleus -With the aim of defining the function of stefin B in the nucleus, we set out to identify proteins that interact with it. Nuclear cell lysates were immunoprecipitated with antistefin B antibodies and separated by SDS-PAGE. The 15-, 14-kDa bands were identified as histones H3, H2B, and H2A.Z by N-terminal protein sequencing (Fig. 1A) . Histone H4 and stefin B were both found around 11 kDa. We found it particularly interesting that stefin B interacts also with the histone H2A.Z variant. The H2A.Z variant is found associated with gene regulatory elements in promoter regions (42) . Recent study proposed that H2A.Z is partly colocalized to the same nucleosome as the H3K4me3 histone variant (43) . An immunoprecipitation experiment confirmed that the H3K4me3 modified histone also coimmunoprecipitated with stefin B in T98G cells ( Fig.1.B) .
Increased expression of stefin B in the nucleus delays cell cycle progression -Incubation of cells with the cysteine protease inhibitor E-64d was reported to delay the entry of cells into S phase of the cell cycle (13, 44) . T98G astrocytoma cells were used for cell cycle experiments, as these cells can be synchronized in G0/G1 in the absence of serum (38, 45) . The effect of E-64d on cell cycle progression was confirmed in synchronized T98G cells (data not shown). Next, we examined whether overexpression of stefin B in the nucleus influences cell cycle progression. T98G cells were transfected with a pEF/myc/nuc vector expressing stefin B pEF/myc/nuc-stefin B (NB), or an empty vector alone (NO). Expression levels of stefin B in stably transfected T98G cells were quantified by ELISA, as described previously (32) . In whole cell lysates of cells stably expressing stefin B the levels of stefin B were 478 ng/mg (ng of stefin B/mg of total cell protein), while in control cells transfected with an empty vector the concentration of stefin B was 178 ng/mg. A marked delay in the progression of cells from the G1 to the S phase was observed in T98G cells overexpressing stefin B, as compared with control T98G cells and cells transfected with the empty vector alone (NO) (Fig. 2, 22h and 26h) .
Stefin B -deficiency leads to accelerated entry into S phase -The influence of stefin B on cell cycle progression was confirmed in mouse embryonic fibroblasts (MEFs) prepared from stefin B-deficient mice and wild type mice. As previously described, the synchronization of MEFs in G0/G1 was not as efficient as for T98G cells (46) . Nevertheless, cell cycle analysis of synchronized MEFs revealed a small but reproducible acceleration of cell cycle progression from the G1 to the S phase at 20 and 22 hours after serum addition in stefin B deficient MEFs. (Fig. 3) . The N-terminally truncated cathepsin L isoform was shown during S phase to localize to the cell nucleus where it cleaves the CUX1 transcription factor (13) . The processed isoforms of CUX1 accelerate entry into S phase and stimulate cell proliferation (46) . We reasoned that the delay in the cell cycle progression in cells overexpressing stefin B in the nucleus could be attributed to the inhibition of cathepsin L by stefin B. Increased expression of stefin B in the nucleus protects CUX1 from cathepsin L cleavage.-Cathepsin L was shown to cleave CUX1 at multiple sites in vitro and in vivo, thereby generating a number of processed isoforms collectively called p110 CUX1 (13) . Proteolytic processing of CUX1 cannot easily be detected by Western blot analysis in T98G cells (A. Nepveu, unpublished). In our experiments we used MCF-7 cells which express large amounts of CUX1. MCF-7 cells were transiently transfected with the pEF/myc/nuc-stefin B expression vector (NB) or an empty vector (NO) and CUX1 expression was monitored by Western blot analysis. We observed diminished cleavage of full length CUX1 protein (p200) and diminished p110 fragment formation in cells overexpressing stefin B, or treated with the cysteine protease inhibitor E64-d, as compared to cells transfected with an empty vector (NO) (Fig. 4) .
The reduction in CUX1 cleavage is consistent with the notion that overexpression of stefin B causes the inhibition of cathepsin L in the nucleus.
Visualization of intracellular M75 cathepsin L -stefin B interactions in the nucleus using FRET -From structural and kinetics studies that investigated the mechanism of cystatin interaction with papain-like cathepsins, we know that the N-terminal part of cystatins is essential for the interaction with enzymes (47, 48) . Therefore a spectral variant of the GFP-TSapphire was fused to the C-terminus of stefin B. Venus-YFP was fused to the N-terminal part of the M75 human cathepsin L variant. M75 truncated variant of cathepsin L was found localized in the nucleus (13) . In CHO-K1 cells, preferential expression of the M75 cathepsin L-YFP fusion protein in the nucleus was observed (Fig. 5.A) . CHO-K1 were chosen for FRET experiments, since they are efficiently transfected (85%) with pcDNA3 expression vector. We used two negative controls: first, a GFP/YFP pair where the two fluorescent proteins are supposed to interact only randomly and second, M75 cathepsin L -YFP and a truncated mutant of stefin B, R68X (Arg68Stop), that is found in EPM1 patients and does not inhibit cathepsin L. The biophysical properties of the R68X mutant have been studied in detail (49) . Spectral bleed-through for YFP (acceptor) was 5,2 ±1,25% and for GFP (donor) was 25,15 ± 0,98%. Images collected in the FRET channel were corrected for donor and acceptor spectral bleed-through and normalized for expression levels (NFRET), as described (41) . NFRET values were measured in the nucleus of 25-30 individual cells for each combination in two separate experiments. (Fig. 5B) . To perform the analysis presented in Fig. 5B , the mean values of the intensity, constructed from the NFRET images recorded over the nucleus, were presented as a scatter plot (Fig. 5C ). When the FRET channel was corrected for the spectral donor (GFP) and acceptor (YFP) bleed-through a NFRET signal in negative control experiments varied between 0 and 20 ( Fig. 5C) . Thus, we have only considered cells with values above a threshold of 20 as positives. In cells transfected with M75 cathepsin L-YFP and stefin B-GFP some of the results were below this threshold (Fig. 5C ), indicating the possibility that endogenous cathepsin L and stefin B present in the nucleus interacted with GFP fusion proteins and interfered with the results. Histones potentiate inhibition of cathepsin L by stefin B -We established that stefin B binds to histones, but the consequences of this interaction are not known. We therefore investigated whether histones influence stefin B inhibitory activity. First, we determined conditions under which inhibition of cathepsin L was in the linear range, i.e. up to 70% inhibition. Next, we tested if purified histones inhibit human cathepsin L in vitro and found that histones did not inhibit cathepsin L activity even at a 100-fold molar excess (2.15µM histone concentration) (Fig. 6A) . To further investigate the role of histones in the inhibition of cathepsin L by stefin B, we preincubated stefin B with increased molar concentrations of histones and measured cathepsin L activity, as described. We found that histone binding to stefin B did not affect the inhibition of cathepsin L by stefin B at lower histone concentration (10.8nM -210nM) (Fig.  6B ), whereas at higher histone concentrations (1.05µM-2.15µM) as found in the nucleus, we observed increased inhibition of cathepsin L by stefin B (Fig. 6B) , Stefin B interacts with histone H3 in the G1 phase of cell cycle -The above results led us to examine if the stefin B interaction with histones is cell cycle dependent. Control T98G cells and T98G cells over-expressing stefin B in the nucleus (NB) were synchronized by serum starvation, as described above. Nuclear lysates were immunoprecipitated with anti-stefin B antibodies and immunoblotting with anti-H3 antibodies showed that most of the binding of stefin B to histone H3 occurred in the G1 phase of the cell cycle (Fig. 7) . In a control experiment membranes immunoblotted with anti-stefin B antibody, confirming the presence of immunoprecipitated stefin B.
Stefin B does not bind DNA -MENT, the serpin that inhibits cathepsin L in the nucleus, is known to bind to histones and DNA, thereby influencing heterochromatin distribution (29, 30) . It was demonstrated that the inhibitory activity of MENT on cathepsin L, rather than DNA binding, is crucial for mediating its effect (29) . DNA was reported to accelerate the rate at which MENT inhibited cathepsin V, a human ortholog of mammalian cathepsin L, up to 50-fold (50) . Therefore, the possible interaction of stefin B with DNA was analyzed by gel shift assay, as previously described (50) . However, stefin B did not bind to DNA, in contrast to cathepsin V, which was used as a positive control (Fig 8) . These results therefore suggest that the interaction of stefin B with histones is different from the binding of serpins like MENT, which react with both histones and DNA.
DISCUSSION
Proteolytic activity of cathepsin L in the nucleus has to be under strict control in order to prevent degradation of transcription factors. Among cystatins, stefin B has been observed in the nucleus, which prompted us to investigate the role of stefin B as a regulator of proteolytic activity of cathepsin L in the nucleus. In this report we describe for the first time an interaction between a nuclear cystatin, stefin B, and the nucleosomal proteins histone H2A.Z, H2B and H3 (Fig. 1A) . The histone H2A.Z variant differs from the canonical H2A in its amino-terminal tail sequence and also at key internal residues. This variant has been implicated in several biological processes, such as gene activation, chromosome segregation, heterochromatin silencing, and progression through the cell cycle (51, 52) . Histones H2A.Z and H3K4me3 are found at promoter regions and it has been suggested that these two histone variants partly co-localize to the same nucleosomes (42, 53) . A co-immunoprecipitation experiment confirmed that the H3K4me3 modified histone also associates with stefin B in T98G cells (Fig. 1B) .
In T98G cells in which stefin B was targeted to the nucleus, we have observed a delay in cell cycle progression into S phase (Fig. 2) . Increased expression of stefin B into the nucleus resulted in a delay in cell cycle progression comparable to treatments with the synthetic cysteine protease inhibitors E-64d or JPM-OEt (13, 44) . Our initial observations were confirmed with the reverse experiment using MEFs from stefin B deficient mice: following exit from quiescence stefin Bdeficient MEFs reached the S phase faster than wild type MEFs (Fig. 3) . Goulet et al. has shown that only shorter procathepsin L isoforms (that start at M56, M75, M77, M81 or M111) could translocate to the nucleus and stimulate processing of the CUX1 transcription factor at the G1/S transition of the cell cycle (13) . The processed p110 CUX1 isoform exhibits distinct DNA binding and transcriptional properties: cells overexpressing p110 CUX1 reached the next S phase faster than control cells (13, 46) . Therefore we hypothesized that the cell cycle delay in cells overexpressing stefin B could be attributed to cathepsin L inhibition in the nucleus. Indeed, the steady-state level of p110 CUX1 was reduced in cells overexpressing stefin B, suggesting that cleavage of CUX1 in the nucleus was partially prevented (Fig. 4) . Interaction of stefin B with the M75 truncated form of cathepsin L in the nucleus was shown by fluorescence resonance energy transfer (FRET) experiments in living cells (Fig 5B, Fig. 5C ). This interaction was not entirely unexpected, as in vitro kinetic studies have shown that stefin B inhibits cathepsin L with a Ki in the picomolar range (54, 55) . Although increased nuclear localization of procathepsin L in ras transformed mouse fibroblasts was reported more than a decade ago (56), the first physiologically relevant substrates of cathepsin L in the nucleus were described only recently (13, 15, 57) . Duncan et al. reported that cathepsin L cleaves histone H3 and proposed that this proteolytic activity plays a role in the development and differentiation of mouse embryonic stem cells (15) . We have examined whether the binding of histones to stefin B affects cathepsin L inhibition. In vitro, high histone concentrations increased the inhibition of cathepsin L by stefin B. Recently, it was shown that cathepsin L is not the only protease present in the nucleus. Although it was proposed by Goulet et al. that a truncated form of cathepsin F could be active in the nucleus, its nuclear activity was reported only recently (13, 58) . Furthermore, Maubach et al. reported that the regulation of nuclear cathepsin F activity by stefin B in hepatic stellate cells was involved in the transcriptional regulation of two activation markers (58). Together these findings suggest that the regulatory activity of stefin B in the nucleus may not be limited to its effect on cathepsin L.
MENT, a serpin that also inhibits cathepsins L and V, strongly blocks cell proliferation and promotes condensation of chromatin (29) . It was shown that MENT-mediated inactivation of cathepsin L, like cathepsin L deficiency, causes a global rearrangement of chromatin structure and redistribution of specifically modified histones (14, 29) . MENT was also reported to interact with DNA (30, 50) . Another cysteine proteaseinhibiting serpin, SCCA-1 (squamous cell carcinoma antigen-1), has also been shown to localize to the nucleus, but unlike MENT, SCCA-1 is unable to bind to DNA (50) . Similarly, we did not observe the binding of stefin B to DNA (Fig 8) . It remains to be tested whether cathepsin inhibitors that do not bind DNA, SCCA-1 and stefin B, have similar effect on heterochromatin redistribution as MENT.
Collectively our results show that stefin B interacts with histones and cathepsin L in the nucleus and regulates cell cycle progression into S phase. Stefin B was bound to histones preferentially during the G1 phase of the cell cycle. In vitro, high concentrations of histones increased the inhibitory effect of stefin B on cathepsin L activity. Interestingly, entry into S phase is delayed similarly in the presence of the cathepsin L inhibitors E-64d and JPM-OEt or following overexpression of stefin B (Fig. 2) and (13, 44) .
In addition to the role of stefin B in preventing unwanted cytosolic protease activity resulting from lysosomal leakage, our results demonstrate that stefin B plays an important role in the regulation of cathepsin L proteolytic activity in the nucleus. Stefin B in the nucleus protects cathepsin L substrates from proteolytic processing and consequently participates in transcriptional regulation. It will be interesting to determine if the loss of cathepsin L inhibition by non-functional mutants of stefin B in EPM1 disease is associated with the excessive cleavage of cathepsin L nuclear substrates.
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